Corticosteroids in ARDS: The never-ending story

Hospital Pharmacy

Volumn 42, Issue 8, 2007, Pages 691-701

  Thomas, Zachariah ^a,b   Kimborowicz, Katarzyna ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c MORRISTOWN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METHYLPREDNISOLONE; PLACEBO;

ADRENAL INSUFFICIENCY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOADING DRUG DOSE; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEPTIC SHOCK; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 34548070469     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4208-691     Document Type: Review

References (48)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319-323.
2. Bernard GR. Acute respiratory distress syndrome: a historical perspective. Am J Respir Crit Care Med. 2005;172:798-806.
3. Lee V, Jain M. Fibroproliferative acute respiratory distress syndrome: a changing paradigm. Clin Pulm Med. 2002;9:315-322.
4. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
5. Meduri GU, Chrousos GP. Effectiveness of prolonged glucocorticoid treatment in acute respiratory distress syndrome: the right drug, the right way? Crit Care Med. 2006;34:236-238.
6. Bellingan GJ. The pulmonary physician in critical care. 6: the pathogenesis of ALI/ARDS. Thorax. 2002;57:540-546.
7. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med. 2001;52:221-237.
8. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax. 1998;53:815-817.
9. Baudouin SV. Manipulation of inflammation in ARDS: achievable goal or distant target? Thorax. 2006;61:464-465.
10. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274:639-644.
11. Vincent JL, Zambon M. Why do patients who have acute lung injury/acute respiratory distress syndrome die from multiple organ dysfunction syndrome? Implications for management. Clin Chest Med. 2006;27:725-731; abstract x-xi.
12. Marshall RP, Bellingan G, Webb S, et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med. 2000;162:1783-1788.
13. Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med. 1997;156:840-845.
14. Liebler JM, Qu Z, Buckner B, Power MB, Rosenbaum JT. Fibroproliferation and mast cells in the acute respiratory distress syndrome. Thorax. 1998;53:823-829.
15. Bellingan GJ, Marshall RP, Laurent GJ. Fibrosis in ARDS: How close is the link between inflammation and fibroproliferation? In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin, Germany: Springer; 2000:217-224.
16. Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. Crit Care. 2004;8:122-129.
17. Schwartz MD, Moore EE, Moore FA, et al. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med. 1996;24:1285-1292.
18. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 2005;12:321-338.
19. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159-165.
20. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-824.
21. Atabai K, Matthay MA. The pulmonary physician in critical care. 5: acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax. 2002;57:452-458.
22. Wheeler AP, Bernard GR, Schoenfeld D, Steinberg K. Methylprednisolone for unresolving ARDS. JAMA. 1998;280:2074.
23. MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22:1140-1156.
24. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocorticol steroids. Chest. 1990;97:138-143.
25. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, el Torkey M, Leeper KV. Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest. 1991;100:943-952.
26. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671-1684.
27. Huang CJ, Lin HC. Association between adrenal insufficiency and ventilator weaning. Am J Respir Crit Care Med. 2006;173:276-280.
28. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S527-S533.
29. Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med. 1979;66:910-914.
30. Henzen C, Suter A, Lerch E, Urbinelli R, Schomo XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355:542-545.
31. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med. 2002;165:983-991.
32. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512-520.
33. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 2003;3:359-366.
34. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288:2859-2867.
35. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med. 2007;175:480-489.
36. Sprung CL, Caralis PV, Marcial EH, et al. The effect of high dose corticosteroids in patients with septic shock. N Engl J Med. 1984;311:1137-1143.
37. Weigelt JA, Norcross JF, Borman KR, Snyder WH. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-540.
38. Bernard GB, Luce JM, Sprung CL, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570.
39. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-68.
40. Annane D, Sebille V, Bellissant E, Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34:22-30.
41. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
42. Dellinger RP. Post hoc analyses in sepsis trials: a formula for disappointment? Crit Care Med. 1996;24:727-729.
43. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064-1069.
44. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954-963.
45. Vieillard-Baron A, Girou E, Valente E, et al. Predictors of mortality in acute respiratory distress syndrome. Focus on the role of right heart catheterization. Am J Respir Crit Care Med. 2000;161:1597-1601.
46. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683-693.
47. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared to traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Eng J Med. 2000;342:1301-1308.
48. Angus DC, Abraham E. Intensive insulin therapy in critical illness. Am J Respir Crit Care Med. 2005;172:1358-1359.